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Background
A high proportion of adults with intellectual disabilities are pre-
scribed off-licence antipsychotics in the absence of a psychiatric
illness. The National Health Service in England launched an ini-
tiative in 2016, ‘Stopping over-medication of people with a
learning disability [intellectual disability], autism or both’
(STOMP), to address this major public health concern.
Aims
To gain understanding from UK psychiatrists working with adults
with intellectual disabilities on the successes and challenges of
withdrawing antipsychotics for challenging behaviours.
Method
An online questionnaire was sent to all UK psychiatrists working
in the field of intellectual disability (estimated 225).
Results
Half of the 88 respondents stated that they started withdrawing
antipsychotics over 5 years ago and 52.3% stated that they are
less likely to initiate an antipsychotic since the launch of STOMP.
However, since then, 46.6% are prescribing other classes of
psychotropic medication instead of antipsychotics for challen-
ging behaviours, most frequently the antidepressants. Complete
antipsychotic discontinuation in over 50% of patients treated
with antipsychotics was achieved by only 4.5% of respondents
(n = 4); 11.4% reported deterioration in challenging behaviours in
over 50% of patients on withdrawal and the same proportion
(11.4%) reported no deterioration. Only 32% of respondents
made the diagnosis of psychiatric illness in all their patients
themselves. Family and paid carers’ concern, lack of multi-
agency and multidisciplinary input and unavailability of non-
medical psychosocial intervention are key reported factors
hampering the withdrawal attempt.
Conclusions
There is an urgent need to develop national guidelines to provide
a framework for systematic psychotropic drug reviews and
withdrawal where possible.
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Individuals with intellectual disabilities are at a higher risk of devel-
oping challenging behaviours (also known as behaviours that chal-
lenge). Although challenging behaviours have been reported in up
to 62%1–4 of adults with intellectual disabilities, more severe chal-
lenging behaviour is reported in a smaller proportion of people
(around 18%).5 Aggression (11%) towards other individuals and
objects and self-injurious behaviour are the most common forms
of challenging behaviour.6 Challenging behaviours in general, and
aggression in particular, pose a major management problem and
are a significant barrier to social integration, and may lead to care-
giver stress, community placement breakdown and use of restrictive
practices. A thorough person-centred assessment with multidiscip-
linary input is vital for successful management. The assessment
should take a biopsychosocial approach by incorporating assess-
ments of the behaviour, the person showing the behaviour, and
medical, psychiatric/psychological and social/environmental
factors.4
Both medications7 and non-medication-based psychosocial
interventions8 are used to manage challenging behaviours.
However, national9 and international10 guidelines recommend the
use of psychosocial intervention first and the use of medication
only when the psychosocial interventions have failed and the
persons themselves or people around them are at a serious risk of
harm. Nevertheless, psychotropic medications are prescribed
widely (32–85%) to people with intellectual disabilities, the
average being around 50–63%.11 Most widely used among psycho-
tropics are the antipsychotics, which are received by 21% of adults
with intellectual disabilities.11 This compares with the rate of anti-
psychotic use of <1% in the general population.12 Antipsychotics
are often used off-licence in intellectual disability in the absence
of a mental illness (36–71%), primarily to manage challenging beha-
viours.13 This shows that the national and international guidelines
need a structure and a support framework for implementation.
The off-licence use of antipsychotics in people with intellectual
disabilities is a major cause of public health concern, as it has been
suggested that every year in England 35 000 adults with intellectual
disabilities receive psychotropic medication unnecessarily,14 and
the long-term use of antipsychotics carries the risk of medication-
related adverse events that could affect the person’s quality of
life.15 As a result, in 2016 the National Health Service (NHS) in
England has embarked on a major campaign, ‘Stopping over-medi-
cation of people with a learning disability [intellectual disability],
autism or both’ (STOMP).16
National9 and international10 guidelines recommend that psy-
chotropic medication should be reviewed regularly, and consider-
ation given to reduction/discontinuation or use for shortest time
possible. One practical way to reduce overmedication in this popu-
lation is to withdraw psychotropics, particularly antipsychotics, by
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tapering dosage. Studies from the UK and The Netherlands
show that it is possible to totally discontinue antipsychotics in
25–46.5% of patients after long-term use and to achieve a dose
reduction of over 50% in a further 11–19% of individuals.17–21
A number of factors have been shown to affect withdrawal. For
example, one of us (D.B)17 found that a lower dose of antipsychotics,
minimal psychopathology, and the lack of aggression, stereotypy
and hyperactivity at baseline helped with the withdrawal. de
Kuijper and colleagues19 found that female gender, a lower rate of
baseline challenging behaviours and lower baseline antipsychotic
dosage are in favour, and the presence of severe challenging beha-
viours, and autonomic and extrapyramidal symptoms at baseline
are factors against a successful withdrawal. They also found that
comorbid autism, a higher dose of antipsychotic, greater severity
of challenging behaviours and higher akathisia scores, andmore fre-
quent worsening of health during withdrawal were associated with a
lower incidence of complete discontinuation. These factors also
affect reinstatement rates.
Although the withdrawal of antipsychotics shows improvement
in challenging behaviours and quality of life among most people, in
some it carries the risk of precipitating withdrawal symptoms that
maymanifest as challenging behaviours.7 However, other possibilities
also need to be considered. For example, behaviour may deteriorate
for reasons that are not at all related to the withdrawal process, so
one should not automatically relate deterioration in behaviour to
the dose reduction or withdrawal. Instead, a thorough assessment
of behaviour should be carried out.4 Sometimes an underlying psychi-
atric disordermay be unmasked onwithdrawal of psychotropicmedi-
cation or dose reduction, particularly if the medication has been used
for a long time. A careful assessment of mental state will be necessary,
as making a diagnosis of a psychiatric disorder in a person with
intellectual disabilities can be difficult.4,22 In some cases, previous
behaviour may return on dose reduction or withdrawal. In these
circumstances, a full functional assessment of the behaviour will be
necessary, including the assessment of predisposing (e.g. genetic
syndromes), precipitating (e.g. life events) and perpetuating (e.g.
inappropriate environment) factors.4 Also, sometimes carers’ anxie-
ties about medication withdrawal may be reflected in a heightened
perception of severity of challenging behaviours on withdrawal.
The aim of the current study was to assess UK psychiatrists’ psy-
chotropic prescribing practice for adults with intellectual disabilities
who display challenging behaviours, with a focus on withdrawal of
antipsychotics.
Method
An online survey using the STROBE cross-sectional study model
was developed through a consultation process by a core team of
psychiatrists, pharmacists and academics working in the field of
psychiatry of intellectual disability, with input from patient repre-
sentative groups. The survey questions can be found in the supple-
mentary material available at https://doi.org/10.1192/bjo.2020.97
(file Supplementary information 1).
The questionnaire with a cover letter was emailed to the UK
Royal College of Psychiatrists’ intellectual disability regional repre-
sentatives and training programme directors practising in the
psychiatry of intellectual disability, who were asked to forward the
questionnaire to the psychiatrists working within their respective
regions. It was supported by the College’s Faculty of Psychiatry of
Intellectual Disability. The survey was open between 12 October
2019 and 29 February 2020 and three email reminders were used
to encourage participation.
The survey took approximately 10 min to complete and con-
tained the following main subsections:
(a) respondent characteristics, such as current medical position,
place of practice, number of years practising psychiatry;
(b) the extent of attempts and the experience of reducing/with-
drawing antipsychotic medication made by that clinician
thus far, for example identifying the proportion of people
with intellectual disabilities in whom respondents have com-
pletely withdrawn antipsychotics;
(c) prescribing habits since the introduction of the STOMP initia-
tive, such as identifying whether respondents are now less
likely to prescribe antipsychotics for challenging behaviours
or are prescribing a different class of psychotropic instead of
antipsychotics;
(d) the structures in place to support the withdrawal of antipsycho-
tics prescribed for challenging behaviours, by looking at
support available and resources developed or used during with-
drawal process, use of outcome measures, confidence in with-
drawing antipsychotics, etc.;
(e) the successes and challenges experienced in withdrawing anti-
psychotics prescribed for challenging behaviours, by looking at
the barriers and challenges that hamper the withdrawal
process, and extra resources required to improve antipsychotic
prescribing practice for challenging behaviours, etc.
Most questions were assessed using multiple choice options or
scales to aid the analysis. Free-text responses were used to gain
data where multiple choice or sliding scales were not suitable and
to gain qualitative data.
Ethics and participation consent
No ethical approval was required as this was a survey of psychia-
trists’ opinion and did not collect any individual patient data. All
potential participants were advised that participation was voluntary,
and their replies would be anonymised before analysis.
Data analysis
Descriptive statistical analyses were carried out primarily to provide
data on proportions, and chi-squared and Fisher’s exact probability
tests, as appropriate, were conducted for intergroup analysis.
Qualitative data were analysed using thematic analysis and will be
reported in a separate paper.
Results
The dissemination of the survey relied on the regional representa-
tives and training programme directors as third parties.We estimate
that around 225 psychiatrists working in the specialty received the
questionnaire, 88 (39%) of whom returned the completed
questionnaire.
Respondents’ characterises
Respondents’ characteristics are described in Table 1.
In total, 28.4% (n = 25) of respondents stated that they have a
database of people with intellectual disabilities/autism spectrum dis-
order who have been prescribed antipsychotics in the absence of a
severe mental illness.
Initiation of antipsychotics for challenging behaviours
Just over half of the respondents (52.3%; n = 46) stated that they
were less likely to initiate an antipsychotic for challenging beha-
viours since the launch of the STOMP initiative. Since the introduc-
tion of the STOMP initiative, 46.6% (n = 41) of participants are
more often prescribing other classes of psychotropic medication
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instead of antipsychotics but 53.4% (n = 47) are not. Among the
other classes of psychotropic prescribed by the 41 respondents,
23.8% reported prescribing antidepressants, 5.7% mood stabilisers,
5.7% benzodiazepines, 4.5% anti-epileptics and 3.8% anxiolytics.
Withdrawing antipsychotics prescribed for challenging
behaviours
Half of the participants started withdrawing antipsychotics more
than 5 years ago, 18.2% started 3–5 years ago, 23.9% 1–3 years
ago, 5.7% less than 1 year ago and 2.3% have not started withdraw-
ing. Apart from antipsychotics, respondents also attempted to with-
draw antidepressants (16%), benzodiazepines (13.3%), mood
stabilisers (12.3%) and anti-epileptics (7.7%).
Over one-third of respondents (36.4%) attempted to withdraw
antipsychotics in more than 50% of patients receiving the drugs
for challenging behaviours, 15.9% in 26–50% and 28.4% in 1–
25%. Only 1.1% of respondents did not attempt to withdraw anti-
psychotics in eligible patients. Withdrawal attempt data were not
available for 17% of the respondents.
Rates of withdrawal, dose reduction and reinstatement
Table 2 contains information on the proportion achieving a success-
ful withdrawal and the rate of reinstatement. Only 4.5% (n = 4) of
respondents achieved a complete withdrawal in over 50% of patients
who were on antipsychotics inappropriately. The majority (60.2%)
(n = 52) achieved this among 1–25%. A slightly better ratio was
reported for over 50% dose reduction, achieved by 9.1% (n = 8)
of respondents in over 50% of patients, compared with 15.9%
(n = 14) in 26–50% of patients and 54.5% (n = 48) in 1–25%
of patients. Reinstatement of antipsychotics was at its highest
within the first 3–6 months but may have increased in some cases
at 12-month follow-up.
Twenty-six respondents (29.5%) who attempted antipsychotic
withdrawal were unsuccessful in achieving a complete withdrawal
in over 50% of patients, 25% (n = 22) were unsuccessful in 26–
50% of patients and 26.1% (n = 23) were unsuccessful in 1–25%.
However, 4.5% (n = 4) of respondents stated that they had never
been unsuccessful in completely withdrawing antipsychotics; this
information was not available for 14.8% (n = 13) of respondents.
Changes in behaviour
A small proportion (11.4%) of respondents stated that behaviour
had deteriorated in over 50% of patients in whom an antipsychotic
withdrawal was attempted and the same proportion (11.4%)
reported no deterioration in their patients on antipsychotic with-
drawal. Additionally, 46.6% noted deterioration in behaviour in
1–25% of patients and 17% in 26–50%.
Factors helping a successful withdrawal
Table 3 describes the reasons provided by the respondents that helped
a successful withdrawal. These included low-dose antipsychotics
(11.7%), antipsychotic monopharmacy (10.8%), first attempt at with-
drawal (9.9%), antipsychotic polypharmacy (9.4%), polypharmacy of
psychotropics (7.5%), experiencing side-effects of medication (7%),
mild intellectual disability (6.6%) and living with family (6.1%).
Antipsychotics prescribed for psychiatric illness
In total, 12.5% of respondents reported that, in over 50% of their
patients who were receiving antipsychotics, they were prescribed
for an underlying psychiatric illness (compared with 13.6% for
26–50% of patients and 15.9% for 1–25% of patients). Therefore,
none of these patients was considered for an antipsychotic with-
drawal. However, 35% of respondents did not have any information
available on this and 1.1% skipped this question.
From response to a subsequent question, it transpired that only
33.2% of respondents had made a diagnosis of mental illness in
their patients themselves. A further 21.4% stated that the psychiatric
diagnosis was made by a colleague, and 30.9% stated that the diagno-
sis was historical and gathered from patients’ case notes; 4.1% stated
that the diagnosis was confirmed by a caregiver, and 7.3% stated that
the diagnosis was gathered from the general practitioner’s (GP’s) case
record. Among those respondents who did not consider antipsychotic
withdrawal in the patients whom they thought had a psychiatric
Table 2 Proportions of patients with successful withdrawals and dose
reductions and the rate of reinstatement (n = 88 respondents)
Proportion of
patients, %
Respondents
n %
Achieved complete
withdrawal from
antipsychotics
0 9 10.2
1–25 53 60.2
26–50 9 10.2
>50 4 4.5
Not available 12 13.6
Not applicable 1 1.1
Achieved >50%
antipsychotic dose
reduction
0 3 3.4
1–25 48 54.5
26–50 14 15.9
>50 8 9.1
Not available 15 17
Antipsychotic reinstated
Within 3 months 0 20 22.7
1–25 45 51.1
26–50 14 15.9
>50 8 9.1
Not available 1 1.1
Within 6 months 0 22 25
1–25 46 52.3
26–50 11 12.5
>50 8 9.1
Not available 1 1.1
Within 12 months 0 31 35.2
1–25 38 43.2
26–50 7 8
>50 11 12.5
Not available 1 1.1
Table 1 Respondents’ characteristics (n=88)
n %
Psychiatrists’ grade
Consultant 87.5
Higher trainee 6.8
Specialty doctor 5.7
Region of practice
London 20.5
South West of England 15.9
South East of England 11.4
East Midlands 10.2
East of England 8
West Midlands 6.8
North East England 5.7
Scotland 5.7
Wales 4.5
Yorkshire and Humber 4.5
Northern Ireland 4.5
Other locations 2.2
Duration of practice in the psychiatry of intellectual disability
Less than 10 years 45.5
10–19 years 35.2
20–29 years 15.9
Withdrawal of antipsychotics for challenging behaviours
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illness, 18.2% were extremely confident and 29.5% moderately confi-
dent in the diagnosis of the psychiatric illness.
Outcome measures
Only one-third (33%, n = 29) of the respondents reported using
outcome measures while withdrawing antipsychotics and 67% (n
= 59) did not use any.
Barriers and support requirement for a successful
antipsychotic withdrawal
Table 4 presents the barriers and support requirements described by the
respondents. Among the barriers, both paid carers’ and family carers’
resistance are rated high. Among the support requirement, multi-
agency working and multidisciplinary team input were rated high.
Intergroup analysis
Intergroup analysis showed no association between overall success
in withdrawing antipsychotics and the professional level of the pre-
scribing psychiatrist (consultant versus trainee) (P = 0.282), the
number of years in practice (P = 0.254) and region of practice
(P = 0.25). There was no association between the likelihood of
initiating antipsychotics in response to STOMP and a psychiatrist’s
position (P = 0.864) or number of years in post (P = 0.093).
A significantly higher proportion of respondents who received
support from local services managed to achieve a complete anti-
psychotic withdrawal (P = 0.001; effect size 0.518).
Discussion
Interestingly, almost one-third (28.4%) of the respondents reported
that they have a database of patients with intellectual disabilities/
autism spectrum disorder who have been prescribed antipsychotics
in the absence of a severe mental illness. If this information reflects a
true trend, and the quality of the databases is good, then it is encour-
aging, although eventually this figure needs to be 100% to facilitate
the antipsychotic withdrawal process.
Initiation of antipsychotics for challenging behaviours
About half of the responders stated that they are less likely to initiate
antipsychotics for challenging behaviours since the launch of the
STOMP pledge. Although this is a welcome move, a high proportion
also stated that they are now prescribing other classes of psychotropic,
in particular antidepressants and benzodiazipines, for this indication.
This goes against the spirit of the STOMP pledge. However, the lack of
non-pharmacological psychosocial support is likely to be one reason
for this increase in prescription of non-antipsychotic psychotropics.
Other studies have shown a similar trend in increase in antidepressant
prescribing.23,24 However, it is also possible that some interpreted the
question incorrectly and may have stated what other class of psycho-
tropic other than antipsychotics they would prescribe if they had to use
medication for challenging behaviours.
Withdrawing antipsychotics prescribed for challenging
behaviours
Half of the respondents started withdrawing antipsychotics more
than 5 years ago. This figure is encouraging. It would have been
interesting to understand whether those supporting withdrawal
approach it in a systematic manner. This is difficult to infer
owing to the lack of standards/guidelines. It is possible that more
of those who are engaged in withdrawal have responded to the
survey, thus creating a reporting bias. However, it also shows that
many psychiatrists were involved in the withdrawal process even
before the introduction of the STOMP initiative.
Just over one-third (36.4%) of respondents reported that they
had tried withdrawal in over 50% of eligible patients (those who
are prescribed antipsychotics for challenging behaviours) and
about one-third (28.4%) tried this in 1–25% of patients. However,
1–25% is a wide range and it is difficult to know what proportion
of respondents attempted withdrawal at the lower end of the
range (say 1–5%).
Total discontinuation versus dose reduction
Only a small number (n = 4) achieved a complete antipsychotic
withdrawal in over 50% of patients (Table 2). Although total discon-
tinuation was not possible in many cases, in some cases a partial
withdrawal in the form of over 50% dose reduction was possible.
This may be because behaviour deteriorated in some cases on
dose reduction and therefore complete discontinuation was not pos-
sible. It is also possible that some of these will eventually achieve a
complete discontinuation of antipsychotics as the dose reduction is
continued in future. The other possibility is that, after complete dis-
continuation, in some cases antipsychotics were reinstated but,
owing to stabilisation of behaviour, the ultimate dose remained
lower than 50% of the original dose.
A greater proportion achieved complete discontinuation among
only 1–25% of patients and we do not know what proportion of
them achieved this at the lower end of the range (say 1–5%). There
was no statistically significant association in the rate of successful with-
drawal and the respondents’ region of practice, duration of practice
and medical position. The reinstatement rate was highest within the
first 3–6 months, which is expected.17,19,20 Previous withdrawal
studies showed a reinstatement rate between 16 and 42%.17,19,20
Withdrawing psychotropics other than antipsychotics
Some respondents reported that, other than antipsychotics for chal-
lenging behaviours, they are also withdrawing antidepressants,
mood stabilisers and anti-epileptic drugs, among others. A system-
atic review found that antidepressants may make challenging beha-
viours worse in some adults with intellectual disabilities, possibly
because of their adverse effects.25 Mood stabilisers reported by the
Table 3 Factors affecting a successful withdrawal (n = 88
respondents)
Factor
Responses
n %
Low-dose antipsychotics 25 11.7
Antipsychotic monopharmacy 23 10.8
First-time withdrawal attempt 21 9.9
Antipsychotic polypharmacy 20 9.4
No factors 19 8.9
Polypharmacy of psychotropics 16 7.5
Experiencing side-effects of medication 15 7
Mild intellectual disability 14 6.6
Living with family 13 6.1
Polypharmacy including physical health drugs and
psychotropics
10 4.7
Psychotropic monopharmacy 9 4.2
High-dose antipsychotics 9 4.2
Other 5 2.3
Data not available 5 2.3
Moderate intellectual disability 2 0.9
Severe behaviours that concern 2 0.9
Severe intellectual disability 2 0.9
Male patient 1 0.5
Female patient 1 0.5
Mild behaviours that concern 1 0.5
Total 213 100
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respondents are likely to be lithium, as they separately reported
about withdrawing anti-epileptics. Previous studies have reported
a lower rate of lithium prescription,17,26 possibly because of its
narrow therapeutic window, serious adverse effect profile and the
difficulty in carrying out necessary blood tests, particularly in
adults with severe and profound intellectual disabilities who show
challenging behaviours.7 Where anti-epileptics have been with-
drawn, it is not clear whether they were initially prescribed for chal-
lenging behaviours or epilepsy, as epilepsy is common in this
population.27
Behaviour change
A small proportion (11.4%) reported a deterioration in behaviour in
over 50% of patients after withdrawal of antipsychotics.
Interestingly, the same proportion (11.4%) reported no such deteri-
oration. In the past, some studies showed either no change in behav-
iour or improvement in behaviour and quality of life on
antipsychotic withdrawal in the majority of patients but others
showed a worsening of behaviour in a high proportion of indivi-
duals.7 A number of studies showed that withdrawal of antipsycho-
tics (particularly the older generation ones: chlorpromazine,
haloperidol, thioridazine) may precipitate extrapyramidal symp-
toms, particularly dyskinesia, Parkinsonism and akathisia.28 These
symptoms may be misinterpreted as challenging behaviours.
Rebound akathisia might appear within the first few days,
whereas rebound Parkinsonism usually emerges after a week and
rebound dyskinesia might only become apparent within a month.
However, most studies also show that these symptoms improve
within a few weeks to months.28 This is an indicator for clinicians
considering withdrawal of antipsychotics that, instead of reinstating
antipsychotics straightaway because of the resurgence of challen-
ging behaviours following antipsychotic withdrawal, they should
wait (if necessary with the help of prescription when required (p.
r.n.)) until the behaviour improves.16
Factors associated with successful withdrawal
The factors described in Table 3 for a successful withdrawal are by
and large the ones that have been reported in previous antipsychotic
withdrawal studies.17–19 However, although some respondents
mentioned antipsychotic monopharmacy as a helpful factor, a
similar number suggested polypharmacy as helpful. This inconsist-
ency is difficult to interpret and, given the small number, a definitive
conclusion is challenging. It is also possible that the way this par-
ticular question was framed had scope for misinterpretation.
These discrepancies highlight the complexity of the withdrawal
process, which is influenced by so many internal and external
factors.28
Antipsychotics prescribed for mental illness
In total, 12.3% of respondents stated that over 50% of their patients
who were receiving antipsychotics had a comorbid psychiatric
illness. Therefore, they did not consider these patients for anti-
psychotic withdrawal. This proportion is very high, compared
with the literature. For example, in a UK population-based study
Sheehan and colleagues11 reported that 71% of adults with intellec-
tual disabilities who were receiving antipsychotics (n = 9135) did
not have a diagnosis of a severe mental illness. However, only
33.2% of respondents made the diagnosis of mental illness them-
selves and the rest depended on diagnosis made by others, including
carer reports and GP records, and in many cases the diagnosis was
historical and gathered from the case notes. The difficulty of making
a diagnosis of a severe mental illness in adults with intellectual dis-
abilities, particularly those who have severe and profound disability,
is well known.3,4,22 It is possible that, although the diagnosis was
made by others, the respondents agreed with it. However, this
may leave room for error and misjudgement, leading to inappropri-
ate use of medication as both false-positive and false-negative diag-
nosis of psychiatric illnesses is possible in people with intellectual
disabilities, particularly when they show challenging behaviours.
It is not uncommon for adults with intellectual disabilities to
have received a psychiatric diagnosis many years ago for which
they have been receiving psychotropics for a long period without
a review. Both national9 and international guidelines10 recommend
a thorough mental state assessment of adults with intellectual dis-
abilities who are receiving psychotropic medication for a diagnosed
or suspected comorbid mental illness. This is even more important
for those who received a psychiatric diagnosis historically (as the
diagnostic criteria have changed over the years) and have been
receiving psychotropics for a long time without a review.
Outcome measures
The majority (67%) of respondents did not use any outcome
measure to assess the effect of the antipsychotic withdrawal. Even
for those who used some outcome measures, the type and quality/
validity of these measures are not known. Both national9,29 and
international10 guidelines recommend use of a validated outcome
measure. At present there is no consistency across the UK in the
type of outcome measures used, and this should be addressed by
developing a national framework for psychiatrists, which should
include recommendation on outcome measures.
Barriers and support requirement for a successful
antipsychotic withdrawal
Many respondents felt that the lack of multi-agency collaboration
(22.4%) and multidisciplinary teamwork (20.1%) are major barriers
in achieving withdrawal. It is also evident from the fact that a stat-
istically significantly higher proportion of those respondents who
reported having received support from their local services achieved
a complete antipsychotic withdrawal compared with those who
reported not having received such support. Multi-agency commit-
ment and involvement are necessary to achieve NHS England’s
‘transforming care’ goals.30 Unwin and colleagues highlighted the
lack of input from the multi-agency team, particularly community
Table 4 Barriers and support requirement for a successful anti-
psychotic withdrawal (n = 88 respondents)
Item Respondents %
Barriers
Resistance from support staff 22.4
Resistance from family carers 20.1
Lack of non-pharmacological psychosocial
interventions
19.5
Lack of Multidisciplinary team support 12.8
Lack of national guidelines on a structure for
withdrawal
7.6
Lack of pharmacist input 7
Reluctance of local GP to get involved 6.1
Lack of competency in withdrawing antipsychotics 4.7
Support required for a successful withdrawal programme
Multiagency working 24.5
Multidisciplinary team input 22.3
Financial help for the patients and the local services 13.3
Nurse prescriber and other allied professionals input 11.2
Social worker input 9.4
Pharmacist input 8.2
GP, general practitioner.
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nurses and clinical psychologists, in dealing with challenging beha-
viours in adults with intellectual disabilities.31 This issue is high-
lighted by the fact that many of our respondents felt that the lack
of available non-pharmacological psychosocial intervention is
often hindering the withdrawal process. Unwin and colleagues pos-
tulated that the lack of input from community nurses may have been
caused by conflicting demand on their time to carry out many tasks
that are not directly related to their professional role.31
Carers’ role
Almost a quarter (22.4%) of respondents reported that concern felt by
support staff and of family carers was a barrier to antipsychotic with-
drawal. A number of authors have highlighted the influence of staff
perception on the withdrawal process.7,18 In a recent survey of
family carers’ views on the management of challenging behaviours
in people with intellectual disabilities, carers expressed a wish to see
a more person-centred multimodal approach to the management
of challenging behaviours for their loved ones. They also highlighted
the need for more involvement of family carers and the person with
intellectual disability in the decision-making process, including deci-
sions on the use of psychotropic medication. Some saw the benefit of
psychotropic medication for challenging behaviours but others felt
that currently inmany areas there may be overreliance on suchmedi-
cation to manage challenging behaviours in people with intellectual
disabilities.32 Many professionals and family carers feel that support
staff would benefit from more knowledge and experience in dealing
with medication for the management of challenging behaviours.
This issue is addressed in a current project which is developing an
online training programme for support staff and family carers
(https://spectrom.wixsite.com/project).33 A family carers’ association,
the Challenging Behaviour Foundation, has also developed online
material for family carers (www.challengingbehaviour.org.uk).
Recommendations
It is difficult tomake robust recommendations on the basis of this small
online survey. However, it highlights the need for a framework/struc-
ture for comprehensive medication review, with a view to withdrawing
inappropriate medication, and training for psychiatrists and other sta-
keholders to support the implementation of the framework.
It is important to conduct a thorough assessment of challenging
behaviours and of the person behind the behaviour, using an appro-
priate structure/framework to provide the right care.34 For example,
consideration of medication must be set within the overall context
of a person-centred care planning. This should involve all stake-
holders, such as the care team members/professionals, support
staff, family carers and, most importantly, the person with intellec-
tual disability, from the outset in all stages of decision-making.
Adherence to national and international guidance for rational pre-
scribing must be monitored by the employers and other authorities
in order to implement these guidelines in day-to-day practice. The
need for non-pharmacological support and intervention should be
continuously pursued.
Psychiatrists must be extra vigilant when assessing any previous
or historical diagnosis of psychiatric illness in people with intellec-
tual disabilities, given the difficulty of making a psychiatric diagno-
sis in this population. Furthermore, there must be a comprehensive
support plan to address any deterioration in behaviour on with-
drawal of medication. This plan has to be agreed at the outset and
monitored on a regular basis by all stakeholders, including family
carers, support staff and the person with intellectual disability.32
Psychiatric training also needs to consider key aspects of how to
diagnose mental illnesses in people with intellectual disabilities in
the presence of coexisting problems such as developmental
disorders, attachment difficulties and trauma, particularly if there
are no reliable informants with knowledge of development histories.
A holistic, multidisciplinary, multi-agency, person-centred
approach should be adopted for a comprehensive medication
review, to reduce overmedication in this population. Our study
showed that two main barriers in implementing antipsychotic with-
drawal were resistance from support staff and resistance from family
carers. Therefore, training for support staff and family carers is
essential (see https://spectrom.wixsite.com/project).
It would be worth repeating a similar survey in future to
measure the impact of any innovations arising from this paper
and any related future work.
Strengths
This is the first attempt to collect data directly fromUK psychiatrists
to assess the effect of STOMP on their psychotropic prescribing
practice. The survey also provides a reflection of real-life practice,
gathering the experience of psychiatrists that can focus further
work that aims to minimise use of antipsychotics for challenging
behaviours.
Weaknesses
The estimated return rate of 39% is low but not unexpected for this
type of survey. It is possible that more psychiatrists who are engaged
in antipsychotic withdrawal have responded to the online survey
than those who are not. This may have introduced bias in the data.
Some questions might be perceived as ambiguous and there may be
some overlap between questions. Relying on psychiatrists’ retrospect-
ive reports and answers is likely to lead to approximations.
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